10x Genomics shares fall 1.26% intraday despite launching Xenium Protein, a new spatial multiomic assay.
ByAinvest
Tuesday, Aug 19, 2025 2:49 pm ET1min read
TXG--
10x Genomics, Inc. declined 1.26% in intraday trading, despite the company launching Xenium Protein, a new addition to its Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell, on the same tissue section, all in a single automated run. This advancement brings RNA and protein data together in situ, unlocking deeper insights into cell function and disease biology.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet